Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

15.51
+0.98006.74%
Post-market: 15.700.1900+1.23%16:16 EDT
Volume:1.15M
Turnover:17.31M
Market Cap:998.14M
PE:-4.47
High:15.56
Open:14.76
Low:14.59
Close:14.53
52wk High:23.19
52wk Low:5.68
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.95
T/O Rate:2.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:3.10
PE(LYR):-4.17

Loading ...

Cullinan’s CLN-978 Lupus Study Opens a New Autoimmune Path for CGEM Investors

TIPRANKS
·
Jun 06

Cullinan Therapeutics to present initial multi-dose clinical data for CLN-978 in rheumatoid arthritis study

Reuters
·
May 26

Stifel Nicolaus Reaffirms Their Buy Rating on Cullinan Management (CGEM)

TIPRANKS
·
May 25

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cullinan Management (CGEM)

TIPRANKS
·
May 20

Cullinan post-EULAR share pullback ‘unwarranted,’ says Clear Street

TIPRANKS
·
May 20

Cullinan Therapeutics wins FDA orphan drug designation for CLN-049 in relapsed AML

Reuters
·
May 19

Cullinan Therapeutics Receives FDA Orphan Drug Designation for Cln-049, a Novel Flt3xcd3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

THOMSON REUTERS
·
May 19

Cullinan Therapeutics Price Target Maintained With a $38.00/Share by BTIG

Dow Jones
·
May 19

Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and Cullinan Management (CGEM)

TIPRANKS
·
May 19

Cullinan presents initial Phase 1 CLN-978 data in refractory RA, SLE at EULAR 2026

Reuters
·
May 19

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

GlobeNewswire
·
May 19

AnaptysBio names Christopher Murphy as CFO

Reuters
·
May 11

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 11

Cullinan Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
May 08

Cullinan Therapeutics price target raised to $37 from $36 at Wedbush

TIPRANKS
·
May 08

Analysts’ Top Healthcare Picks: Cullinan Management (CGEM), Neumora Therapeutics, Inc. (NMRA)

TIPRANKS
·
May 08

Cullinan Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Cullinan Therapeutics Q1 EPS $(0.75) Beats $(0.87) Estimate

Benzinga Earnings
·
May 07

Cullinan Therapeutics Q1 net loss widens

Reuters
·
May 07

BRIEF-Cullinan Therapeutics Q1 Operating Expenses USD 53.697 Million

Reuters
·
May 07